BTG2 is a recently recognized tumor suppressor belonging to the TOB/BTG family, and a study shows that BTG2 expression is reduced in NSCLC tissues and is linked to shorter OS for patients (Chen et al., 2020). Here, TOB1 is linked to non-small cell lung carcinoma.